OnCo

Create your OnCo account

One account keeps your watchlist, saved views and cancer choice in sync across your devices, and lets OnCo alert you when a trial or treatment you follow changes. No password: we email you a sign-in link.

Account creation is being switched on. Until then, press Watch on any page and your list stays in this browser.

Cancers & treatments·Sequencing

Chronic lymphocytic leukaemia, first treatment: lines of therapy

Cancer page →

4 standard-of-care settings across 3 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

LineAll comers
Early / localised1
Advanced, first line2
Other settings1

Early / localised

SubgroupSettingApproachProducts and trialsEvidence
All comersAsymptomatic early-stage diseaseWatch and wait with counts every three to twelve months; treat only on iwCLL indications.
Flow cytometry (immunophenotyping)IGHV mutational statusdel(17p) / TP53 aberration in CLLCytogenetics and FISH
95

Advanced, first line

SubgroupSettingApproachProducts and trialsEvidence
All comersFirst treatment, fixed durationVenetoclax plus obinutuzumab for 12 months (CLL14, CLL13); ibrutinib-venetoclax (GLOW, CAPTIVATE) or acalabrutinib-venetoclax with or without obinutuzumab (AMPLIFY) for fit patients.
VenetoclaxObinutuzumabCLL14CLL13 / GAIAIbrutinibAcalabrutinibGLOWCAPTIVATEAMPLIFYVenetoclax + obinutuzumab (12 months)BTK inhibitor + venetoclax, fixed duration
95
All comersFirst treatment, continuousAcalabrutinib (ELEVATE-TN) or zanubrutinib (SEQUOIA) until progression, preferred for del(17p) or TP53-mutated disease; ibrutinib where the newer agents are unavailable.
AcalabrutinibZanubrutinibIbrutinibELEVATE-TNSEQUOIACaution: ibrutinib in patients with cardiac risk
95

Other settings

SubgroupSettingApproachProducts and trialsEvidence
All comersChemoimmunotherapyFludarabine-cyclophosphamide-rituximab or bendamustine-rituximab only for IGHV-mutated disease without TP53 aberration where targeted drugs are unavailable; never for del(17p).
FludarabineCyclophosphamideRituximabBendamustineChlorambucilCaution: chemoimmunotherapy in del(17p)/TP53 CLL
83

Sequence and caution pairings

CautionApproved
Caution: chemoimmunotherapy in del(17p)/TP53 CLL

Chemotherapy-based regimens barely work when the p53 gene is lost; these patients need BTK inhibitors or venetoclax from the start.

CautionApproved
Caution: ibrutinib in patients with cardiac risk

Ibrutinib raises the risk of irregular heart rhythm, high blood pressure, and sudden cardiac events; second-generation BTK inhibitors are safer choices for patients with heart disease.

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.